MedTrace Logo

Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis

NCT07689942 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-07-08

No results posted yet for this study

Summary

This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a clinical trial. The objective is to provide access to eRapa based on the treating physician's assessment that the potential benefits outweigh the potential risks, with appropriate clinical monitoring for safety and tolerability.

Conditions

  • Familial Adenomatous Polyposis (FAP)

Interventions

DRUG

eRapa (encapsulated rapamycin)

eRapa is a proprietary oral encapsulated formulation of rapamycin (sirolimus) provided as 0.5 mg capsules. This expanded access program uses the 0.5 mg formulation specifically developed for long-term administration.

Sponsors & Collaborators

  • Biodexa Pharmaceuticals

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07689942 on ClinicalTrials.gov